MX2024008629A - Derivados del azaindol y su uso como inhibidores de la erk-cinasa. - Google Patents
Derivados del azaindol y su uso como inhibidores de la erk-cinasa.Info
- Publication number
- MX2024008629A MX2024008629A MX2024008629A MX2024008629A MX2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A
- Authority
- MX
- Mexico
- Prior art keywords
- erk
- kinase inhibitors
- azaindol
- derivatives
- azaindol derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305031.1A EP4212531A1 (en) | 2022-01-14 | 2022-01-14 | Azaindole derivatives and their use as erk kinase inhibitors |
| PCT/EP2023/050692 WO2023135233A1 (en) | 2022-01-14 | 2023-01-13 | Azaindole derivatives and their use as erk kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008629A true MX2024008629A (es) | 2024-08-19 |
Family
ID=80445694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008629A MX2024008629A (es) | 2022-01-14 | 2023-01-13 | Derivados del azaindol y su uso como inhibidores de la erk-cinasa. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11827637B2 (https=) |
| EP (2) | EP4212531A1 (https=) |
| JP (1) | JP2025502377A (https=) |
| KR (1) | KR20240134887A (https=) |
| CN (1) | CN118541370A (https=) |
| AR (1) | AR128267A1 (https=) |
| AU (1) | AU2023207276A1 (https=) |
| CA (1) | CA3242894A1 (https=) |
| CL (1) | CL2024002070A1 (https=) |
| CO (1) | CO2024008809A2 (https=) |
| IL (1) | IL314199A (https=) |
| JO (1) | JOP20240157A1 (https=) |
| MX (1) | MX2024008629A (https=) |
| TW (1) | TW202334147A (https=) |
| UA (1) | UA130477C2 (https=) |
| WO (1) | WO2023135233A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4212531A1 (en) * | 2022-01-14 | 2023-07-19 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| WO2025012386A1 (en) * | 2023-07-12 | 2025-01-16 | Agv Discovery | Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor |
| WO2025012357A1 (en) * | 2023-07-12 | 2025-01-16 | Ipsen Pharma | Fluorinated azaindole derivatives and their use as erk kinase inhibitors |
| CN121511244A (zh) * | 2023-07-12 | 2026-02-10 | Agv探索公司 | (s)-1-(1-(3-氯苯基)-2-(二甲氨基)乙基)-4-(5-吗啉代-1h-吡咯并[2,3-b]吡啶-3-基)吡啶-2(1h)-酮的盐，其制备及其作为erk激酶抑制剂的用途 |
| EP4588918A1 (en) | 2024-01-18 | 2025-07-23 | AGV Discovery | Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one |
| WO2026064271A1 (en) | 2024-09-23 | 2026-03-26 | Fmc Corporation | Substituted bicyclic amide derivatives as herbicides |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| UA84930C2 (ru) | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения |
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| CN100396678C (zh) | 2004-11-16 | 2008-06-25 | 财团法人工业技术研究院 | 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途 |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| AU2007275221A1 (en) | 2006-07-20 | 2008-01-24 | Allen J. Borchardt | Benzothiophene inhibitors of RHO kinase |
| EP2102189B1 (en) | 2006-12-15 | 2015-07-29 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| WO2012094313A1 (en) | 2011-01-04 | 2012-07-12 | Kinentia Biosciences Llc | Pyrazole derivatives as erk inhibitors |
| EP2739143B1 (en) | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| MX2015004615A (es) | 2012-10-16 | 2015-07-17 | Hoffmann La Roche | Inhibidores de serina/treonina cinasa. |
| GB2515785A (en) | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| EP3247353A4 (en) | 2015-01-23 | 2018-07-04 | Confluence Life Sciences, Inc. | Heterocyclic itk inhibitors for treating inflammation and cancer |
| EP3170822A1 (en) | 2015-11-18 | 2017-05-24 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| EP3551651B1 (en) | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| BR112021009430A2 (pt) * | 2018-11-16 | 2021-08-17 | California Institute Of Technology | inibidores de erk e usos dos mesmos |
| EP4212531A1 (en) * | 2022-01-14 | 2023-07-19 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
-
2022
- 2022-01-14 EP EP22305031.1A patent/EP4212531A1/en not_active Withdrawn
- 2022-12-30 TW TW111150950A patent/TW202334147A/zh unknown
-
2023
- 2023-01-13 CA CA3242894A patent/CA3242894A1/en active Pending
- 2023-01-13 UA UAA202403575A patent/UA130477C2/uk unknown
- 2023-01-13 CN CN202380016949.8A patent/CN118541370A/zh active Pending
- 2023-01-13 AU AU2023207276A patent/AU2023207276A1/en active Pending
- 2023-01-13 JP JP2024542357A patent/JP2025502377A/ja active Pending
- 2023-01-13 US US18/096,996 patent/US11827637B2/en active Active
- 2023-01-13 WO PCT/EP2023/050692 patent/WO2023135233A1/en not_active Ceased
- 2023-01-13 IL IL314199A patent/IL314199A/en unknown
- 2023-01-13 EP EP23700812.3A patent/EP4463453A1/en active Pending
- 2023-01-13 AR ARP230100088A patent/AR128267A1/es unknown
- 2023-01-13 KR KR1020247023085A patent/KR20240134887A/ko active Pending
- 2023-01-13 MX MX2024008629A patent/MX2024008629A/es unknown
- 2023-10-06 US US18/377,633 patent/US12421231B2/en active Active
-
2024
- 2024-07-03 CO CONC2024/0008809A patent/CO2024008809A2/es unknown
- 2024-07-09 CL CL2024002070A patent/CL2024002070A1/es unknown
- 2024-07-14 JO JOJO/P/2024/0157A patent/JOP20240157A1/ar unknown
-
2025
- 2025-08-28 US US19/313,201 patent/US20260042758A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12421231B2 (en) | 2025-09-23 |
| UA130477C2 (uk) | 2026-02-25 |
| WO2023135233A1 (en) | 2023-07-20 |
| JP2025502377A (ja) | 2025-01-24 |
| TW202334147A (zh) | 2023-09-01 |
| CO2024008809A2 (es) | 2024-08-08 |
| CN118541370A (zh) | 2024-08-23 |
| AU2023207276A1 (en) | 2024-08-01 |
| AR128267A1 (es) | 2024-04-10 |
| EP4212531A1 (en) | 2023-07-19 |
| US11827637B2 (en) | 2023-11-28 |
| US20260042758A1 (en) | 2026-02-12 |
| US20230227451A1 (en) | 2023-07-20 |
| IL314199A (en) | 2024-09-01 |
| US20240308997A1 (en) | 2024-09-19 |
| EP4463453A1 (en) | 2024-11-20 |
| CA3242894A1 (en) | 2025-02-28 |
| CL2024002070A1 (es) | 2024-11-29 |
| KR20240134887A (ko) | 2024-09-10 |
| JOP20240157A1 (ar) | 2024-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008629A (es) | Derivados del azaindol y su uso como inhibidores de la erk-cinasa. | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| CO2022010098A2 (es) | Inhibidores de proteínas kras mutantes | |
| AR119207A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| GEAP202416075A (en) | New macrocyclic lrrk2 kinase inhibitors | |
| MX381041B (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| MX391410B (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| ECSP10010272A (es) | Derivados bis-(sulfonilamino) para uso en terapia | |
| CO6361936A2 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
| DOP2010000148A (es) | Derivados bis-(sulfonilzmino) en terapia 066 | |
| BR112015022993A8 (pt) | inibidores de jak2 e alk2 e métodos para sua utilização. | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| UY36152A (es) | Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo | |
| UY37028A (es) | Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds | |
| UY32585A (es) | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa | |
| CO2022010878A2 (es) | Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a | |
| CR11433A (es) | Inhibidores de quinasa c-fms | |
| CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| BR112022002222A2 (pt) | Derivados de quinolina como inibidores de proteínas quinases | |
| MX2024011130A (es) | Inhibidor de derivados heterociclicos que contienen nitrogeno, metodo de preparacion y utilizacion del mismo | |
| CL2025002505A1 (es) | Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3. |